UNITED STATES SECURITIES AND EXCHANGE COMMISSION JANUARY 30, 2012

ORDER GRANTING CONFIDENTIAL TREATMENT UNDER THE SECURITIES EXCHANGE ACT OF 1934

Anika Therapeutics, Inc.

File No. 001-14027 - CF#27762

Anika Therapeutics, Inc. submitted an application under Rule 24b-2 requesting confidential treatment for information it excluded from the Exhibits to a Form 8-K filed on December 22, 2011.

Based on representations by Anika Therapeutics, Inc. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit will not be released to the public for the time period specified:

Exhibit 10.1 through December 21, 2021

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Sebastian Gomez Abero Special Counsel